Context colorectal cancer is the third most common form of cancer and the fifth most frequent cause of cancer deaths in China and has a tendency to increase year by year. Primary treatment of advanced colorectal cancer still is chemotherapy, and chemotherapy can cause non-alcoholic hepatic steatosis. Hepatic metastasis is the most common metastatic pathway in colorectal cancer patients, and about 50% of colorectal cancer will eventually develop hepatic metastasis, among which colon cancer combined hepatic metastasis is about 15% to 25%, while others are metachronous liver metastases. The incidence of hepatic metastasis is higher in colorectal cancer with hepatic steatosis, but there is also evidence that hepatic steatosis which can reduce the incidence of liver metastasis. Chemotherapy and target therapy for colorectal cancer are commonly used in past studies have found that cause the hepatic steatosis, and the hepatic steatosis increased with the increase of chemotherapy time and period. Prevent therapy with cholestasis or enzymatic drugs can improve the liver function injury. If have hepatic steatosis, the postoperative residual liver volume increased, and due to the change of liver texture, the risk of intraoperative hemorrhage increased significantly and the difficulty of hemostasis increased, leading to a significant increase in the risk of surgery. Study hepatic steatosis cause by chemotherapy have an influence on therapy of hepatic metastasis of colorectal carcinoma has very realistic clinical significance.